Wegrzyn RD, Appiah GD, Morfino R, Milford SR, Walker AT, Ernst ET, Darrow WW, Li SL, Robison K, MacCannell D, Dai D, Girinathan BP, Hicks AL, Cosca B, Woronoff G, Plocik AM, Simen BB, Moriarty L, Guagliardo SAJ, Cetron MS, and Friedman CR
We enrolled arriving international air travelers in a severe acute respiratory syndrome coronavirus 2 genomic surveillance program. We used molecular testing of pooled nasal swabs and sequenced positive samples for sublineage. Traveler-based surveillance provided early-warning variant detection, reporting the first US Omicron BA.2 and BA.3 in North America., Competing Interests: Potential conflicts of interest. R. D. W., R. M., S. L. L., K. R., D. D., B. P. G., A. L. H., B. C., G. W., A. M. P., and B. B. S. are employed by Ginkgo Bioworks and own Ginkgo Bioworks employee stocks and/or Restricted Stock Units (RSU) grants. S. R. M., E. T. E., and W. W. D. are employed by the XpresSpa Group and own employee stocks and/or RSU grants. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed., (© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.)